ASH 2010

This phase 3 study on Remission Rates in Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen With or Without Gemtuzumab Ozogamicin was recently completed by Alan S. Gamis, MD, MPH, of the Children’s Mercy Hospitals and Clinics in Kansas City, Mo., and colleagues. The findings from this study were presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

An ongoing evaluation has shown comparable rates of secondary myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and other secondary neoplasia (sNPL) among 3 treatment regimens: bendamustine plus rituximab (B-R); cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R); and fludarabine-rituximab (F-R). The data was presented at the 52nd American Society of Hematology Meeting and Exposition.

Despite prior therapy with novel agents, the combination of lenalidomide, bortezomib, and dexamethasone (RVD) is very active and well tolerated in patients with relapsed and relapsed/refractory multiple myeloma after >2 years of follow-up have shown. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

In a heavily pretreated population with multiple myeloma, the combination of bendamustine and bortezomib appears to be safe and effective, results of an open-label phase 1 study have found. The phase 2 study was presented at the 52nd American Society of Hematology Meeting and Exposition and is ongoing.

Combination cytokine immunotherapy is well tolerated and effective in patients with aplastic anemia and has activity in a subset of patients with myelodysplastic syndrome (MDS), updated results of a phase 2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition concluded.

Oral ezatiostat demonstrated clinically significant efficacy in patients with myelodysplastic syndromes (MDS) who were both lenalidomide-naïve and lenalidomide-treated, a phase 2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has shown.

For older patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not transplant candidates or may not tolerate aggressive therapy with its associated higher toxicity, bendamustine (B) plus rituximab (R) may have a treatment role, results of an ongoing study presented at the 52nd American Society of Hematology Annual Meeting and Exposition suggest.

A retrospective study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has found that patients with FL-3 treated with aggressive chemotherapy regimens have improved outcomes when rituximab is added to the therapy. In fact, in the “rituximab era,” the outcome of patients with FL-3 is comparable to DLBCL, a population that also benefits from treatment with rituximab and chemotherapy, reported Philip J. Bierman, MD, University of Nebraska Medical Center, Omaha, Neb., and colleagues.

The combination of rituximab plus vinorelbine, ifosfamide, mitoxantrone, and prednisone (R-NIMP) is well tolerated, yields a high complete response rate, and allows for successful mobilization of CD34+ cells in patients with diffuse large B-cell lymphoma (DLBCL) in first relapse, results of a phase 2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.